NEW BREAST CANCER DRUG TO HELP MORE PATIENTS
A new class of drug, designed to treat less common cases of breast cancer, could benefit up to one in five women with the disease, a study suggests.The drugs, known as PARP inhibitors, treat women with breast cancer related to inherited mutations in the BRCA1 and BRCA2 genes – a type of cancer that became well known when Angelina Jolie shared her experience with it.
Published in the journal Nature Medicine, the study involved researchers from more than 30 medical institutions.They took DNA from breast cancer tumours removed from 560 people and did whole genome sequencing. From there they developed a computer programme to recognise genetic “signatures” linked to the mutations. These results were then compared to those from people with non-inherited breast cancer.
Leggete l'articolo completo e molti altri in questo numero di
Women’s Running
Opzioni di acquisto di seguito
Se il problema è vostro,
Accesso per leggere subito l'articolo completo.
Singolo numero digitale
Jun 2017
Questo numero e altri numeri arretrati non sono inclusi in un nuovo
abbonamento. Gli abbonamenti comprendono l'ultimo numero regolare e i nuovi numeri pubblicati durante l'abbonamento. Women’s Running
Abbonamento digitale annuale
Plus the last 3 back issues for free
Adesso €42,99
fatturati annualmente